Growth-focused healthcare and life sciences private investment firm Petrichor has named Paul J Sekhri as Operating Partner, bolstering its team with an executive who brings more than 35 years of experience across biotech and pharmaceutical sectors.
Sekhri, currently Chairman, President, and CEO of vTv Therapeutics, has held senior leadership positions at eGenesis, Lycera Corporation, and Cerimon Pharmaceuticals, in addition to strategic roles at Sanofi, Teva, TPG Biotech, ARIAD Pharmaceuticals, and Novartis. He also serves on more than 40 public and private company boards, including Veeva Systems, Kayothera, and Deep Genomics, and holds chairmanships at Resolution Therapeutics and Violet Therapeutics.
Petrichor Founder and Managing Partner Tadd Wessel described Sekhri as “a proven leader across biotech and big pharma whose expertise will strengthen our ability to support healthcare innovators at all stages of development.”
Petrichor has completed over 125 healthcare investments, deploying more than $6bn in capital, and holds extensive board representation across its portfolio.
